Formation of Neurofibrillary Tangles in P301L Tau Transgenic Mice Induced by Aβ42 Fibrils-Reference-Cited by-同舟云学术

Formation of Neurofibrillary Tangles in P301L Tau Transgenic Mice Induced by Aβ42 Fibrils

Published:2001-08-24 Issue:5534 Volume:293 Page:1491-1495
ISSN:0036-8075
Container-title:Science
language:en
Short-container-title:Science

Author:

Götz J.¹,Chen F.¹,van Dorpe J.²,Nitsch R. M.¹

Affiliation:

1. Division of Psychiatry Research, University of Zürich, August Forel Strasse 1, 8008 Zürich, Switzerland.

2. Experimental Genetics Group, Center for Human Genetics, K. U. Leuven, Campus Gasthuisberg, Leuven, Belgium.

Abstract

β-Amyloid plaques and neurofibrillary tangles (NFTs) are the defining neuropathological hallmarks of Alzheimer's disease, but their pathophysiological relation is unclear. Injection of β-amyloid Aβ 42 fibrils into the brains of P301L mutant tau transgenic mice caused fivefold increases in the numbers of NFTs in cell bodies within the amygdala from where neurons project to the injection sites. Gallyas silver impregnation identified NFTs that contained tau phosphorylated at serine 212/threonine 214 and serine 422. NFTs were composed of twisted filaments and occurred in 6-month-old mice as early as 18 days after Aβ 42 injections. Our data support the hypothesis that Aβ 42 fibrils can accelerate NFT formation in vivo.

Publisher

American Association for the Advancement of Science (AAAS)

Subject

Multidisciplinary

Reference38 articles.

1. Neurofibrillary tangles, amyotrophy and progressive motor disturbance in mice expressing mutant (P301L) tau protein

2. Tau Filament Formation in Transgenic Mice Expressing P301L Tau

3. Tau and transgenic animal models

4. To generate transgenic mice we introduced the human pathogenic tau mutation P301L into the cDNA encoding the longest human brain tau isoform by a polymerase chain reaction (PCR)–mediated approach. This isoform contained exons 2 and 3 as well as four microtubule-binding repeats (2 + 3 + 4R htau40). To discriminate P301L tau transgenic from wild-type tau transgenic mice we introduced a silent mutation into the P301L construct that destroys a diagnostic Sma I restriction site. The cDNA was conferred with a Kozak consensus sequence and was subcloned into a murine Thy.1.2 genomic expression vector (provided by H. van der Putten Novartis Basel). Vector sequences of this construct (named pR5) were removed before microinjection. Transgenic mice were produced by pronuclear injection of B6D2F1 × B6D2F1 embryos. Founders were identified by PCR analysis of lysates from tail biopsies with two different primer pairs. Founder animals were intercrossed with C57BL/6 mice to establish lines. Transgenic mice were screened with oligonucleotides tau-I (5′-GGAGTTCGAAGTGATGGAAG-3′) and tau-K (5′-GGTTTTTGCTGGAATCCTGG-3′) and yielded an amplification product of 500 base pairs. A restriction digest of the amplification product by Sma I confirmed the presence of the P301L transgene. Of 10 independent transgenic lines 4 had comparable expression levels as determined by immunoblot analysis. Line pR5-183 was used in the present study.

5. K. B. J. F. a. G. Paxinos The Mouse Brain in Stereotaxic Coordinates (Academic Press San Diego 1997).

Cited by 1334 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. In Silico Prediction of Quercetin Analogs for Targeting Death-Associated Protein Kinase 1 (DAPK1) Against Alzheimer’s Disease;Current Neuropharmacology;2024-12

2. Near-infrared laser diode mitigates Aβ1–42-induced neurodegeneration in cortical neurons;Journal of Photochemistry and Photobiology B: Biology;2024-10

3. In 2024, the amyloid-cascade-hypothesis still remains a working hypothesis, no less but certainly no more;Frontiers in Aging Neuroscience;2024-09-04

4. Increased between-network connectivity: A risk factor for tau elevation and disease progression;Neuroscience Letters;2024-09

5. Molecular mechanism and therapeutic strategy of bile acids in Alzheimer’s disease from the emerging perspective of the microbiota–gut–brain axis;Biomedicine & Pharmacotherapy;2024-09